AGENUS INC — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Agenus completed an oversubscribed $85M private placement in July 2026 with milestone-aligned warrants potentially providing up to $255M more, funding the Phase 3 ROBBIN trial of botensilimab+balstilimab in neoadjuvant MSS colon cancer (estimated 38,000 annual U.S. patients; $7B+ sales opportunity). Q2 2026 revenue was $34.5M ($6.4M pre-commercial BOT+BAL product revenue; $28.1M non-cash royalty revenue). ROBBIN initiation and first-patient dosing expected Q1 2027. Company discontinued BATTMAN Phase 3 trial funding to prioritize resources toward ROBBIN.
Why this rating
Major financing relative to $135M market cap (63% raise); funds multi-year program through 2031 if warrants exercised. Initiates pivotal trial in large underserved market with established clinical rationale. Moderately dilutive but strategically transformational for lead program.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.